Arian Lundberg

Key publications

01. Lundberg A, Zhang M, Aggarwal R, Li H, Zhang L, Foye A, Sjöström M, Chou J, Chang K, Moreno-Rodriguez T, Shrestha R, Baskin A, Zhu X, Weinstein AS, Younger N, Alumkal JJ, Beer TM, Chi KN, Evans CP, Gleave M, Lara PN, Reiter RE, Rettig MB, Witte ON, Wyatt AW, Feng FY, Small EJ, Quigley DA. Title: The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer. Journal: Cancer Research. Volume 83, Issue 16

02. Calì B, Troiani M, Bressan S, Attanasio G, Merler S, Moscarda V, Mosole S, Ricci E, Guo C, Yuan W, Gallagher L, Lundberg A, Bernett I, Figueiredo I, Alvarez Arzola R, Bermudez Abreut E, D’Ambrosio M, Bancaro N, Brina D, Zumerle S, Pasquini E, Maddalena M, Lai P, Colucci M, Pernigoni N, Rinaldi A, Minardi D, Morlacco A, Dal Moro F, Sabbadin M, Galuppini F, Fassan M, Rüschoff JH, Moch H, Rescigno P, Francini E, Saieva C, Modesti M, Theurillat JP, Gillessen S, Wilgenbus P, Graf C, Ruf W, de Bono J, Alimonti A. Title: Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer. Journal: Cancer Cell (September 19, 2024).

03. Zhao SG, Bootsma M, Zhou S, Shrestha R, Moreno-Rodriguez T, Lundberg A, Pan C, Arlidge C, Hawley JR, Foye A, Weinstein AS, Sjöström M, Zhang M, Li H, Chesner LN, Rydzewski NR, Helzer KT, Shi Y, West Coast Dream Team Consortium, Lynch M, Dehm SM, Lang JM, Alumkal JJ, He HH, Wyatt AW, Aggarwal R, Zwart W, Small EJ, Quigley DA, Lupien M, Feng FY. Title: Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer. Journal: Nature Genetics. Volumn 56, pages 1689–1700 (2024)

04. Zhang M, Sjöström M, Cui X, Foye A, Farh K, Shrestha R, Lundberg A, Dang HX, Li H, Febbo PG, Aggarwal R, Alumkal JJ, Small EJ, The SU2C/PCF West Coast Prostate Cancer Dream Team, Maher CA, Feng FY, Quigley DA. Title: Integrative analysis of ultra-deep RNA-seq reveals alternative promoter usage as a mechanism of activating oncogenic programmes during prostate cancer progression. Journal: Nature Cell Biology. Volume 26, pages 1176–1186 (2024).

05. Lundberg A, Yi JJ, Lindström LS, Tobin NP. Title: Reclassifying tumour cell cycle activity in terms of its tissue of origin. Journal: npj Precision Oncology. Volume 6, Article number: 59 (2022).

06. Lundberg A, Li B, Li R. Title: B cell-related gene signature and cancer immunotherapy response. Journal: British Journal of Cancer, volume 126, pages 899–906 (2022).

In my team, we’re investigating how inflammation and the microbiome contribute to cancer progression, with a focus on genitourinary cancers such as prostate and bladder cancer. Inflammation is increasingly recognized as a key driver in cancer development, and our goal is to decode how interactions between the microbiome and the tumor microenvironment shape these inflammatory processes. Positioned at the convergence of oncology and microbiology, our work seeks to leverage microbiome insights to enhance precision medicine in cancer treatment.

While most microbiome research to date has centered on bacterial and viral communities within the gut, we are filling an important gap by studying the intra-tumoral microbiome, specifically, how microbial communities within tumors impact inflammatory responses, interact with cancer therapies, and influence treatment outcomes. We’re particularly interested in how these complex interactions drive cancer progression and lineage plasticity in tumors, and how they can be targeted for better treatment strategies.

To achieve our goals, we’re taking a multi-omics approach, integrating genomics, transcriptomics, and proteomics, backed by advanced computational and data science methods. Working with unique Swedish patient cohorts, we collaborate nationally and internationally, creating an expansive research network. These partnerships enable us to take on ambitious questions and create predictive models that hold promise for transforming cancer treatment.

Our vision is to determine whether the tumor microbiome is a fundamental feature of the tumor microenvironment linked to cancer progression, and to develop precise, adaptive prediction models that can guide personalized treatment. With one of the largest coordinated efforts to study the tumor microbiome, my lab is advancing research through extensive clinical cohorts and developing a robust, flexible pipeline that can extend across cancer types. By working toward Pan-Cancer applications, we aim to drive meaningful advances in cancer intervention and prevention.

Last updated: 2024-11-06

Content Responsible: Hampus Persson(hampus.persson@scilifelab.uu.se)